Effects of oestrogen receptor-active compounds on lipid metabolism

Diabetes, Obesity and Metabolism

Volumn 7, Issue 5, 2005, Pages 471-477

  Lakoski, Susan G ^a   Herrington, David M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Lipid metabolism; Selective oestrogen receptors modulators; Tibolone

Indexed keywords

ESTROGEN RECEPTOR; LIPID; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE;

BREAST CANCER; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; EUROPE; HUMAN; LIPID METABOLISM; MENOPAUSAL SYNDROME; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT;

EID: 23844455995     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00412.x     Document Type: Review

References (38)

1. Grundy SM. Cholesterol and Atherosclerosis. Philadelphia: J.B. Lippincott Co, 1990.
2. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000; 86: 5L-10L.
3. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106: 2526-2529.
4. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106: 2537-2542.
5. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875-881.
6. Westerveld HT, van Lennep JE, van Lennep HW et al. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol 1998; 18: 1101-1107.
7. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000; 53: 487-496.
8. Craig WY, Ledue TB. Lipoprotein (a) and the acute phase response. Clin Chim Acta 1992; 210: 231-232.
9. Li XN, Grenett HE, Benza RL et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp (a) in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 3215-3223.
10. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290: 932-940.
11. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-439.
12. Mosca L, Harper K, Sarkar S et al. Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia. Clin Ther 2001; 23: 1552-1565.
13. Selective Estrogen Receptor Modulators (SERMs). Bethesda: Annals of the New York Academy of Sciences, 2001.
14. Vrbanec D, Reiner Z, Belev B, Plestina S. Changes in serum lipid and lipoprotein levels in postmenopausal patients with node-positive breast cancer treated with tamoxifen. Tumori 1998; 84: 687-690.
15. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-1647.
16. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003; 88: 2135-2140.
17. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003; 42: 698-704.
18. Walsh BW, Paul S, Wild RA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 214-218.
19. Cushman M, Costantino JP, Tracy RP et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001; 21: 255-261.
20. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001; 93: 16-21.
21. Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (multiple outcomes of raloxifene evaluation) randomized trial. JAMA 2002; 287: 847-857.
22. von Eckardstein A, Crook D, Elbers J et al. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin Endocrinol (Oxf) 2003; 58: 49-58.
23. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001; 76: 231-238.
24. Kloosterboer HJ, Benedek-Jaszmann LJ, Kicovic PM. Long-term effects of Org OD 14 on lipid metabolism in post-menopausal women. Maturitas 1990; 12: 37-42.
25. Ederveen AG, Kloosterboer HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 2001; 16: 1651-1657.
26. Berning B, Kuijk CV, Kuiper JW, Bennink HJ, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996; 19: 395-399.
27. Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000; 36 (Suppl. 4): S76-S77.
28. Colacurci N, Mele D, De Franciscis P, Costa V, Fortunato N, De Seta L. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol 1998; 80: 235-238.
29. Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003; 362: 419-427.
30. Farish E, Barnes JF, Fletcher CD, Ekevall K, Calder A, Hart DM. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen. Menopause 1999; 6: 98-104.
31. Barnes JF, Farish E, Rankin M, Hart DM. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis 2002; 160: 185-193.
32. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.
33. von Eckardstein A, Schmiddem K, Hovels A et al. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis 2001; 159: 433-439.
34. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
35. Morris EP, Denton ER, Robinson J, MacDonald LM, Rymer JM. High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure. Climacteric 1999; 2: 13-20.
36. Garnero P, Jamin C, Benhamou CL, Pelissier C, Roux C. Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum G-reactive protein in healthy post-menopausal women: a randomized trial. Hum Reprod 2002; 17: 2748-2753.
37. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 2001; 103: 1497-1502.
38. Doran PM, Riggs BL, Atkinson EJ, Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001; 16: 2118-2125.